Simulations Plus

For Simulations Plus clients, our experts are able to offer:

• machine learning to assist with drug design efforts
• bridge physiologically based pharmacokinetic and biopharmaceutics modeling (PBPK & PBBM) with pharmacometrics
• population PK/PD analyses
• provide expanded pharmacodynamic modeling
• noncompartmental analysis in a validated environment with submission-ready report
• NONMEM & Monolix analysis

• developing custom quantitative systems pharmacology and toxicology (QSP QST) models to support pre-clinical/clinical drug development
• application of existing validated QSP & QST models in drug-induced liver damage (DILI), acute kidney injury (AKI), metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), idiopathic pulmonary fibrosis (IPF), and heart failure to support regulatory interactions and internal decision making
• and assist with data assembly, analysis, and reporting for internal decision makings and global regulatory interaction